Daily Respiratory Research Analysis
Three standout respiratory studies advance mechanisms, risk prediction, and therapeutic targets. A mechanistic paper shows the SARS-CoV-2 spike RGD motif activates TGF-β via integrins and suppresses type I interferon. A large cohort-plus-mediation analysis links ambient air pollution to COPD and lung function decline through lipid, inflammatory, and hematologic biomarkers. Multi-omic profiling identifies creatine/SLC6A8 dependency as a metabolic vulnerability in lung squamous cell carcinoma.
Summary
Three standout respiratory studies advance mechanisms, risk prediction, and therapeutic targets. A mechanistic paper shows the SARS-CoV-2 spike RGD motif activates TGF-β via integrins and suppresses type I interferon. A large cohort-plus-mediation analysis links ambient air pollution to COPD and lung function decline through lipid, inflammatory, and hematologic biomarkers. Multi-omic profiling identifies creatine/SLC6A8 dependency as a metabolic vulnerability in lung squamous cell carcinoma.
Research Themes
- Viral pathogenesis and immune evasion (integrin–TGF-β axis)
- Environmental exposure and COPD risk with biomarker mediation
- Tumor metabolism and therapeutic targeting in lung cancer
Selected Articles
1. An RGD motif on SARS-CoV-2 Spike induces TGF-β signaling and downregulates interferon.
The study demonstrates that the SARS-CoV-2 spike RGD motif activates integrin-dependent TGF-β/SMAD3 signaling, induces PAI-1, and suppresses IFN-β, thereby weakening antiviral defense. Mutating the RGD motif or blocking it with ATN-161 abrogated signaling, highlighting an S–integrin axis as a therapeutic target and with potential relevance to post-acute sequelae of COVID-19.
Impact: Reveals a concrete mechanistic axis by which SARS-CoV-2 modulates host immunity via integrins, suggesting new intervention points beyond ACE2. It unifies pro-fibrotic signaling with interferon suppression.
Clinical Implications: Integrin antagonists or TGF-β pathway modulators could be evaluated to mitigate acute disease severity and post-acute sequelae. RGD-targeted strategies might restore antiviral responses or reduce profibrotic remodeling.
Key Findings
- Spike RGD motif triggers integrin-dependent TGF-β signaling and SMAD3-mediated PAI-1 expression.
- RGD mutation or the RGD antagonist ATN-161 abolished TGF-β activation, implicating integrins.
- Spike RGD via TGF-β suppresses IFN-β expression, impairing cellular antiviral defenses.
- ACE2 is required for TGF-β activation by spike in the tested systems.
Methodological Strengths
- Convergent validation across recombinant protein, pseudotyped virus, and infected cells.
- Genetic (RGD mutation) and pharmacologic (ATN-161) perturbations clarify causality.
Limitations
- Lack of in vivo validation limits direct translational inference.
- Cell-type and context specificity of integrin usage was not exhaustively mapped.
Future Directions: Test integrin/TGF-β inhibitors in vivo and assess effects on viral load, interferon signaling, and fibrotic remodeling; evaluate implications in long COVID.
UNLABELLED: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein mediates canonical cell entry via ACE2 and has also been implicated as an activator of a diverse range of signaling pathways. Here, we present evidence that the RGD (Arg-Gly-Asp) motif within the receptor-binding domain (RBD) of the S1 fragment of the S protein induces TGF-β cytokine expression. RGD peptides are well characterized as ligands for a subset of integrin complexes primarily containing α5 and αV subunits. In this study, we investigate the molecular basis of TGF-β pathway activation by S protein, delivered to cells as recombinant protein, in pseudotyped virus or in virally infected cells. Activation of TGF-β signaling by the S protein requires ACE2 and leads to SMAD3-dependent expression of the pro-fibrotic marker PAI-1. Utilizing pseudotyped viruses, expression of the S protein with a mutated RGD motif abolished TGF-β signaling, as did the RGD antagonist ATN-161, implicating integrin complexes in mediating this response. We show that the S protein RGD motif suppresses IFN-β expression via TGF-β, leading to a disruption in cellular antiviral defenses, consistent with TGF-β's role in immunosuppression. These findings further support the multifunctionality of S protein and provide mechanistic insights into its activity as a virulence factor during infection. IMPORTANCE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an ongoing public health challenge as a cause of acute illness and post-acute sequelae of COVID-19 (PASC, or long COVID). Our study identifies the RGD integrin-binding motif in the spike (S) protein as central to the cellular response to SARS-CoV-2, leading to the expression of the pleiotropic cytokine TGF-β and disabling of antiviral immunity. This work further supports the S protein-to-integrin complex signaling axis as a potential therapeutic target. The RGD motif might also be a valid target for treating PASC given the increasing body of evidence implicating the presence of persistent S protein in the etiology of this disease.
2. Ambient air pollution exposure, mediating biomarkers and risk of COPD: a cohort study and meta-analysis.
Using 451,566 UK Biobank participants and meta-analysis, the study shows that ambient air pollution exposure is associated with lung function decline and increased COPD risk. Lipid, inflammatory, and hematologic biomarkers partially mediate these associations, with disproportionate impact observed in White populations.
Impact: Links a ubiquitous exposure to COPD via biologically plausible pathways at population scale, informing prevention and policy. Mediation by measurable biomarkers provides mechanistic and interventional leverage.
Clinical Implications: Supports intensified air quality policies and individualized risk assessment using biomarker panels; motivates early screening and preventive strategies in high-exposure groups.
Key Findings
- Ambient air pollution exposure is associated with accelerated lung function decline and elevated COPD risk.
- Lipid, inflammatory, and hematologic biomarkers mediate part of the air pollution–COPD relationship.
- Disproportionately higher impact was observed among White populations in this analysis.
Methodological Strengths
- Very large prospective cohort (UK Biobank, n=451,566) with standardized exposure estimation (land use regression).
- Formal mediation analysis and meta-analytic synthesis enhance mechanistic inference and generalizability.
Limitations
- Residual confounding and exposure misclassification are possible in observational designs.
- Truncated reporting in abstract limits access to exact effect estimates and pollutant-specific results.
Future Directions: Integrate longitudinal biomarker trajectories and multi-omics to refine mediation; evaluate targeted interventions (e.g., air purifiers, statins/anti-inflammatories) in high-risk subgroups.
BACKGROUND: Limited evidence exists on air pollution's systemic impact on lung function and mediating biomarkers. This study comprehensively evaluated associations between air pollution, COPD and lung function, while exploring biomarker mediation. METHODS: A prospective analysis of 451 566 UK Biobank participants was conducted. Land use regression models estimated exposure to particulate matter (PM) ≤2.5 μm (PM RESULTS: Elevated PM CONCLUSION: Air pollution associates with lung function decline and elevated COPD risk, with White populations disproportionately affected. Lipid, inflammatory and haematological biomarkers mediate this relationship. Findings underscore the urgency of air pollution control to mitigate respiratory harm and inform targeted preventive and therapeutic strategies.
3. Multi-omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma.
Integrated transcriptomics and metabolomics of resected lung cancers revealed elevated creatine and tumor cell–associated overexpression of the creatine transporter SLC6A8 as SqCC-specific features. These data nominate SLC6A8 as a therapeutic target based on a metabolic addiction hypothesis.
Impact: Defines a metabolically addicted state (creatine/SLC6A8) in SqCC with direct translational implications, aligning with existing drug development in other cancers.
Clinical Implications: Supports biomarker development (creatine/SLC6A8) for SqCC and rationalizes testing SLC6A8 inhibitors; may refine patient selection for metabolism-targeted trials.
Key Findings
- Seven SqCC-specific metabolites were identified; creatine was notably elevated in SqCC.
- SLC6A8, the creatine transporter, showed tumor cell–associated overexpression in SqCC.
- Integration of gene expression with metabolomics (Reactome, GEMs) highlighted metabolic functions unique to SqCC.
Methodological Strengths
- Multi-omic integration with validation across tumors, normal tissues, and cell lines.
- In situ protein assessment (SLC6A8) supports cellular localization and relevance.
Limitations
- Functional inhibition of SLC6A8 was not assessed in vivo to demonstrate therapeutic efficacy.
- Sample size and cohort composition details are not provided in the abstract.
Future Directions: Preclinical testing of SLC6A8 inhibitors in SqCC models; develop imaging or blood biomarkers for creatine/SLC6A8 to stratify patients.
Squamous cell lung carcinoma (SqCC) is the second most common histological subtype of lung cancer. Besides tumor-initiating and promoting DNA, RNA, and epigenetic alterations, aberrant cell metabolism is a hallmark of carcinogenesis. This study aimed to identify SqCC-specific key regulators that could eventually be used as new anticancer targets. Transcriptional and metabolomic data were gathered for a cohort of resected lung cancers. SqCC-specific differentially expressed genes were integrated with metabolic data. Findings were validated in cohorts of tumors, normal specimens, and cell lines. In situ protein expression of SLC6A8 was investigated. Differential gene expression analysis identified a subset of SqCC-specific genes with metabolic functions through the Reactome database, and/or correlated to specific metabolites through GEMs models. Metabolic profiling identified seven SqCC-specific metabolites, of which increased creatine levels, in particular, matched to SqCC-specific expression of SLC6A8. Expression of the gene appeared tumor cell-associated. Elevated creatine levels and overexpression of its transporter SLC6A8 appear a distinct metabolic feature of SqCC. Considering ongoing clinical trials in other malignancies, exploring SLC6A8 inhibition in SqCC appears motivated based on a metabolic addiction hypothesis.